Zhongsheng Pharmaceutical's Unit Gets Patent From Japan for Polypeptide Drug

MT Newswires Live

Jul 21

Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.

The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.

This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2653276202"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2653276202\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2653276202?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-21 16:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2653276202","market":"nz","top_or_hot":-1,"title":"Zhongsheng Pharmaceutical's Unit Gets Patent From Japan for Polypeptide Drug","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/002317\">Guangdong Zhongsheng</a> Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.</p><p>The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.</p><p>This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhongsheng Pharmaceutical's Unit Gets Patent From Japan for Polypeptide Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhongsheng Pharmaceutical's Unit Gets Patent From Japan for Polypeptide Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-21 16:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/002317\">Guangdong Zhongsheng</a> Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.</p><p>The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.</p><p>This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2653276202","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2653276202","pubTimestamp":1784621836,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangdong Zhongsheng Pharmaceutical's  unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0077":"质押式回购","002317":"众生药业","USRD":"THEMES US R&D CHAMPIONS ETF","BK0239":"医药制造","BK0188":"融资融券"},"translate_title":"众生药业子公司获得日本多肽药物专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002317":0.9,"USRD":0.9},"content_text":"Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}